* Note: Prices are in Million (M) USD.
Description:
Iovance Biotherapeutics, Inc. is a pioneering clinical-stage biotechnology company based in San Carlos, California, dedicated to advancing cancer immunotherapy through innovative cell therapy solutions. The company's proprietary tumor-infiltrating lymphocyte (TIL) therapy aims to leverage and enhance the patient’s immune response to combat various cancer types, with a current focus on melanoma and cervical cancer. With a robust pipeline and a commitment to scientific excellence, Iovance is positioned to address significant unmet medical needs in oncology, making it a compelling investment opportunity in the rapidly evolving field of cancer treatment.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $132 M
Debt : $8 M
EBITDA : $-362 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 17 overlapping fiscal years (max 20).Average Free Cash Flow: $-118 M
Average Revenue: $10 M
Revenue Converted To Free Cash Flow (%): -1,210.6%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $164 M
Revenue 5 Years Ago (2019-12-31): $0 M
Total Growth over 5 Years: 0.0%
5-Year Revenue CAGR (Historical): 0.0%
Forward 5-Year CAGR (Tapered): 0.0%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $290 M
Share Count 5 Years Ago (2020-12-31): $138 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-0.66
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-0.66
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 14 valid ROE years (max 20).Average ROE: -245.3%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $2.21
52-Week Low: $1.64
Threshold Price (15% Above 52-Week Low): $1.89
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $800 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 1% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 7 points to above Iovance Biotherapeutics Inc (IOVA) stock.
Fair Value PE 9, Industry Based PE 15, Risk-Free Anchored PE (25% MoS) 18.2. Based on these 3 values, average assigned is 14.07. The fair value of Iovance Biotherapeutics Inc (IOVA) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
